A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China  by Zhu, Qing et al.
Clinical Biochemistry 46 (2013) 1047–1054
Contents lists available at SciVerse ScienceDirect
Clinical Biochemistry
j ourna l homepage: www.e lsev ie r .com/ locate /c l inb iochemA novel polymorphism of the CYP2J2 gene is associated with coronary
artery disease in Uygur population in China
Qing Zhu 1, Zhenyan Fu 1, Yitong Ma ⁎, Hong Yang, Ding Huang, Xiang Xie, Fen Liu,
Yingying Zheng, Erdenbat Cha
Department of Cardiovascular Medicine, First Afﬁliated Hospital of Xinjiang Medical University, Urumqi, China⁎ Corresponding author at: Department of Cardiovas
Hospital of Xinjiang Medical University, Li Yu Shan Sou
China. Fax: +86 991 4366191.
E-mail address: myt-xj@163.com (Y. Ma).
1 These authors contributed equally to this work.
0009-9120 © 2013 The Authors. The Canadian Society
http://dx.doi.org/10.1016/j.clinbiochem.2013.05.003a b s t r a c ta r t i c l e i n f oArticle history:
Received 17 February 2013
Received in revised form 13 April 2013
Accepted 3 May 2013
Available online 15 May 2013
Keywords:
CYP2J2
Single nucleotide polymorphism
Coronary artery disease
Case–control study
Background: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachi-
donic acid to biologically active epoxyeicosatrienoic acids (EETs). The EETs are potent endogenous vasodilators
and inhibitors of vascular inﬂammation. The aim of the present study was to assess the association between the
human CYP2J2 gene polymorphism and coronary artery disease (CAD) in a Han and Uygur population of China.
Methods:Weuse two independent case–control studies: a Han population (206 CAD patients and 262 control
subjects) and an Uygur population (336 CAD patients and 448 control subjects). All CAD patients and controls
were genotyped for the same three single nucleotide polymorphisms (SNPs) (rs890293, rs11572223 and
rs2280275) of CYP2J2 gene by a real-time PCR instrument.
Results: In the Uygur population, for total, the distribution of SNP3 (rs2280275) genotypes showed a signif-
icant difference between CAD and control participants (P = 0.048). For total and men, the distribution of SNP3
(rs2280275) alleles and the dominant model (CC vs CT + TT) showed a signiﬁcant difference between CAD and
control participants (for allele: P = 0.014 and P = 0.035, respectively; for dominant model: P = 0.014 and
P = 0.034, respectively). The signiﬁcant difference in dominantmodelwas retained after adjustment for covariates
(OR: 0.279, 95% conﬁdence interval [CI]: 0.176–0.440, P = 0.001; OR: 0.240, 95% CI: 0.128–0.457, P = 0.001,
respectively).
Conclusions: The CC genotype of rs2280275 in CYP2J2 gene could be a protective genetic marker of CAD and
T allele may be a risk genetic marker of CAD in men of Uygur population in China.© 2013 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
Open access under CC BY license.1. Introduction
Coronary artery disease (CAD) is a complex multifactorial and poly-
genic disorder thought to result from an interaction between an
individual's genetic makeup and different environments [1,2]. Various
gene variants have been shown to be associated with CAD [3,4]. The
cytochromep450 (CYP) enzymes are a super-family of cysteinato-heme
enzymes [5,6]. They are responsible for not only themetabolism of xeno-
biotics but also a host of endogenous substance whose metabolites have
critical roles in the maintenance of cardiovascular health [7,8]. Mounting
evidences have demonstrated that CYP enzymes are involved in the path-
ogenesis of CAD. Polymorphisms of CYP genes, for example, CYP1A1,cular Medicine, First Afﬁliated
th Road 137, Urumqi 830054,
of Clinical Chemists. Published by ECYP1A2, andCYP1B1 (metabolize tobacco-smokepolycyclic aromatic hy-
drocarbons and 17-beta-estradiol) [9–11], CYP2C8, CYP2C9, and
CYP2J2 (synthesis of EETs) [12–14], CYP2C19 (involved in clopidogrel
metabolism) [15], CYP3A4 (main metabolic enzyme of fentanyl) [16],
CYP4A11 and CYP4F2 (synthesis of 20-hydroxyeicosatetraenoicacid)
[17,18], CYP8A (prostacyclin synthesis) [19], and CYP11B2 (aldosterone
synthesis) [20] have been demonstrated to have a relationship with
CAD. In the human heart, EETs are mainly produced by CYP2J2 [21],
which play an important role in the regulation of cardiovascular inﬂam-
mation [22], and possess potent vasodilatory, antiapoptotic properties
in the cardiovascular system [14,23,24]. Commonpolymorphismswith-
in CYP2J2 can result in the variation of EETs, whichmay determine sus-
ceptibility to the development of cardiovascular disease.
Recently, some reports on the cardiovascular risk associated with
CYP2J2 polymorphisms have provided inconsistent results. The studies
by Spiecker M, Liu PY and Lee showed that a polymorphism of the
CYP2J2 gene (rs890293) was associated with CAD and MI [14,25,26].
Therewere several studies suggesting no signiﬁcant association between
the polymorphism of CYP2J2 (rs890293) and CAD or MI [27–29]. Based
on the above background, we aimed to assess the association between
the polymorphism of CYP2J2 and CAD in a Han and Uygur population
of China.lsevier Inc. Open access under CC BY license.
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2.1. Ethical approval of the study protocol
Written informed consent was obtained from all participants. All par-
ticipants explicitly provided permission for DNA analyses as well as col-
lection of relevant clinical data. This study was approved by the Ethics
Committee of the First Afﬁliated Hospital of Xinjiang Medical University
(Urumqi, China). It was conducted according to the standards of the
Declaration of Helsinki.
2.2. Subjects
The subjects were from a Han population and an Uygur population
who lived in the Xinjiang Uygur Autonomous Region of China. All pa-
tients and controls had a differential diagnosis for chest pain encountered
in the Cardiac Catheterization Laboratory of First Afﬁliated Hospital of
Xinjiang Medical University from 2006 to 2012. All of the procedures of
coronary angiography were undertaken by highly skilled physicians
using the Judkins approach. The ﬁndings of coronary angiography were
interpreted by a least two experienced imaging specialists and the ﬁnal
diagnosis of CAD was made according to the angiography report.
We recruited randomly 206 Han patients and 336 Uygur patients
with CAD and 262 and 448 ethnically and geographically matched con-
trol group. All CAD groups deﬁned as the presence of at least one signif-
icant coronary artery stenoses of more than 50% luminal diameter on
coronary angiography. All control subjects also underwent a coronary
angiogram and have no coronary artery stenoses and did not show clin-
ical or electrocardiogram evidence of myocardial infarction (MI) or
CAD. Control subjects were not healthy individuals, some of them
have hypertension, some of them have DM, and some of them have
hyperlipidemia,whichmeans control group expose to the same risk fac-
tors of CAD while the results of coronary angiogram are normal. Data
and information about traditional coronary risk factors, including hy-
pertension, diabetes mellitus (DM), and smoking, were collected from
all study participants. The diagnosis of hypertension was established if
patients were on antihypertensive medication or if the mean of 3 mea-
surements of systolic blood pressure (SBP) >140 mm Hg or diastolic
blood pressure (DBP) >90 mm Hg, respectively. Diabetes mellitus
was diagnosed according to the criteria of the American Diabetes Asso-
ciation [30]. In addition, individuals with fasting plasma glucose
>7.0 mmol/L or with a history of diabetes or treatment with insulin
were considered diabetic. Smokingwas classiﬁed as smokers (including
current and ex-smokers) or non-smokers. All patients with impaired
renal function, malignancy, connective tissue disease, valvular disease
or chronic inﬂammatory disease were excluded.5’ 
(kbp)0 20
 Exon1
CYP2J2 gene
rs2280
(SNP
rs11572223
(SNP2)
10
rs890293
(SNP1)
2 3 4 5 
Fig. 1. Structure of the human CYP2J2 gene. This gene consists of 9 exons separated by 8 intr
indicate coding regions. Arrows mark the locations of polymorphisms.2.3. Blood collection and DNA extraction
Fasting blood samples drawn by venipuncture in the catheter-room
were taken from all participants before cardiac catheterization. The
blood samples were drawn into a 5 mL ethylene diamine tetraacetic
acid (EDTA) tube and centrifuged at 4000 ×g for 5 min to separate the
plasma content. Genomic DNA was extracted from the peripheral
leukocytes using standard phenol–chloroform method. The DNA sam-
ples were stored at−80 °C until use. While used, the DNA was diluted
to 50 ng/μL concentration.2.4. Genotyping
There are 701 SNPs for the human CYP2J2 gene listed in the National
Center for Biotechnology Information SNP database (http://www.ncbi.
nlm.nih.gov/SNP). Using the Haploview 4.2 software and the HapMap
phrase II database, we obtained three tag SNPs (rs890293, rs11572223
and rs2280275) by usingminor allele frequency (MAF)≤0.1 and linkage
disequilibrium patterns with r2 ≥ 0.5 as a cut off. The position of the
SNP1, SNP2 and SNP3 (rs890293, rs11572223 and rs2280275) was by
order of increasing distance from the CYP2J2 gene 5′ end (Fig. 1). SNP1
(rs890293) was observed in the proximal promoter region of the gene.
The polymorphisms caused a loss of transcription factor binding site Sp1.
Genotyping was undertaken using the TaqMan® SNP Genotyping
Assay (Applied Biosystems). The primers and probes used in the
TaqMan® SNPGenotyping Assays (ABI)were chosen based on informa-
tion at the ABI website (http://myscience.appliedbiosystems.com).
Thermal cycling was done using the Applied Biosystems7900HT
Standard Real-Time PCR System. Plates were read on Sequence
Detection Systems (SDS) automation controller software v2.3 (ABI).
PCR ampliﬁcation was performed using 2.5 μL of TaqMan Universal
Master Mix, 0.15 μL probes and 1.85 ddH2O in a 6-μL ﬁnal reaction
volume containing 1 μL DNA. Thermal cycling conditions were as
follows: 95 °C for 5 min; 40 cycles of 95 °C for 15 s; and 60 °C for
1 min. All 96 well plates were read on Sequence Detection Systems
(SDS) automation controller software v2.3 (ABI).2.5. Biochemical analysis
Serum concentrations of total cholesterol (TC), triglyceride (TG),
glucose (Glu), high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C), were measured using standard
methods in the Central Laboratory of First Afﬁliated Hospital of Xinjiang
Medical University.STOP
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Table 1
Characteristics of study participants.
Han Uygur
Total Men Women Total Men Women
CAD
patients
Control
subjects
P
value
CAD
patients
Control
subjects
P
value
CAD
patients
Control
subjects
P
value
CAD
patients
Control
subjects
P
value
CAD
patients
Control
subjects
P
value
CAD
patients
Control
subjects
P
value
Number (n) 206 261 156 141 50 120 336 448 272 186 64 262
Age (years) 58.69 ±
7.50
57.76 ±
8.01
0.401 59.97 ±
8.119
58.60 ±
8.51
0.231 58.13 ±
6.28
59.85 ±
6.89
0.061 55.97 ±
5.75
54.93 ±
5.59
0.076 55.57 ±
8.32
53.96 ±
9.05
0.090 53.20 ±
3.88
51.30 ±
4.82
0.066
BMI (kg/m2) 27.73 ±
3.84
28.04 ±
2.85
0.349 26.54 ±
1.89
26.23 ±
1.82
0.175 30.76 ±
1.84
30.06 ±
2.10
0.054 31.34 ±
7.19
27.11 ±
4.36
0.001* 30.45 ±
6.83
27.48 ±
3.97
0.001* 31.97 ±
7.39
25.73 ±
5.40
0.001*
Pulse (beats/min) 73.16 ±
10.12
73.72 ±
10.02
0.554 73.19 ±
10.43
74.77 ±
11.16
0.213 73.06 ±
9.18
72.51 ±
8.40
0.706 75.59 ±
10.91
77.56 ±
7.92
0.390 74.49 ±
11.21
75.76 ±
8.46
0.733 77.91 ±
9.75
81.38 ±
5.18
0.339
Glu (mmol/L) 6.08 ±
2.41
5.44 ±
1.56
0.001* 5.79 ±
1.71
5.37 ±
1.33
0.024* 6.37 ±
3.07
5.30 ±
1.44
0.001* 6.50 ±
2.79
5.14 ±
2.39
0.001* 6.31 ±
2.63
5.10 ±
2.54
0.001* 7.21 ±
3.24
5.17 ±
2.30
0.001*
TG (mmol/L) 1.97 ±
1.32
1.98 ±
1.84
0.951 1.81 ±
0.92
1.67 ±
0.79
0.190 2.17 ±
1.76
1.79 ±
1.09
0.115 1.83 ±
1.25
1.76 ±
1.35
0.435 1.77 ±
0.99
1.83 ±
1.50
0.638 2.10 ±
2.07
1.70 ±
1.24
0.061
TC (mmol/L) 4.18 ±
1.06
4.32 ±
0.95
0.169 4.09 ±
1.03
4.22 ±
0.93
0.313 4.45 ±
1.14
4.44 ±
0.90
0.960 4.14 ±
1.07
4.05 ±
0.99
0.240 4.08 ±
1.05
4.03 ±
0.96
0.564 4.40 ±
1.14
4.07 ±
0.96
0.027*
HDL (mmol/L) 1.08 ±
0.33
1.15 ±
0.33
0.027 1.05 ±
0.28
1.18 ±
0.45
0.535 1.18 ±
0.45
1.23 ±
0.32
0.416 0.99 ±
0.23
1.02 ±
0.22
0.143 0.98 ±
0.30
0.99 ±
0.24
0.738 1.054 ±
0.30
1.05 ±
0.20
0.802
LCL (mmol/L) 2.47 ±
0.88
2.16 ±
0.90
0.001* 2.44 ±
0.84
2.11 ±
0.81
0.001* 2.50 ±
0.92
2.18 ±
0.97
0.001* 2.76 ±
0.85
2.49 ±
0.96
0.001* 2.80 ±
0.83
2.46 ±
0.98
0.001* 2.74 ±
0.86
2.62 ±
0.88
0.355
EH (%) 58.25 46.56 0.012* 60.50 42.29 0.002* 56.00 50.83 0.022* 41.67 17.41 0.001* 33.34 19.30 0.001* 50.00 15.52 0.001*
DM (%) 25.73 12.21 0.001* 20.46 14.42 0.001* 32.00 10.00 0.001* 25.60 11.83 0.001* 20.52 6.72 0.001* 29.68 16.94 0.001*
Smoke (%) 59.22 33.97 0.001* 86.44 55.94 0.001* 12.00 2.5 0.001* 32.14 16.96 0.001* 62.72 33.89 0.001* 1.56 0 –
BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; Glu, glucose; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; EH, essential hypertension; DM, diabetes mellitus.
Continuous variable were expressed as mean ± standard deviation. P value of continuous variables was calculated by independent T-test.
The P value of categorical variable was calculated by Fisher's exact test. *P b 0.05.
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All continuous variables (e.g. age, BMI, pulse, cholesterol levels) are
presented asmeans ± standard deviation (S.D.). The difference between
the CAD and control groups was analyzed using an independent-sample
T-test. The differences in the frequencies of smoking, hypertension,
diabetes mellitus, and CYP2J2 genotypes were analyzed using χ2 test or
Fisher's exact test while appropriate. Hardy–Weinberg equilibrium was
assessed by χ2 analysis. Logistic regression analyses with effect ratios
(odds ratio [OR] and 95% CI) were used to assess the contribution of the
major risk factors. All statistical analyses were performed using SPSS
17.0 for Windows (SPSS Institute, Chicago, USA). P-values of less than
0.05 were considered to statistically signiﬁcant.
3. Results
Table 1 shows the clinical characteristics of the study participants.
For Han and Uygur populations, there was no signiﬁcant difference in
age between CAD patients and control subjects. It means the study
was an age-matched case–control study. In Han population, for total,
men, and women, the plasma concentration of Glu, and LDL-C and the
prevalence of essential hypertension (EH), diabetes mellitus (DM),
and smoking were signiﬁcantly higher for patients with CAD than for
control participants. In Uygur population, for total and men, BMI, the
plasma concentration of Glu, and LDL-C and the prevalence of EH, DM,
and smoking were signiﬁcantly higher for patients with CAD than for
control participants. For women, BMI, the plasma concentration of
Glu, and TC and the prevalence of EH, DM, and smoking were signiﬁ-
cantly higher for patients with CAD than for control participants.
Tables 2a and 2b show the distribution of genotypes and alleles of
SNP1, SNP2 and SNP3 for the CYP2J2 gene (a: Han population; b:UygurTable 2a
Genotype and allele distributions in patients with CAD and control subjects (Han populatio
Total
CAD n (%) Control n (%) P
rs890293
(SNP1)
Genotype Dominant model G/G 521 (90.92) 411 (90.33) –
T/T 1 (0.17) 0 (0.00)
G/T 51 (8.90) 44 (9.67)
GG 521 (90.92) 411 (90.33) 0
GT + TT 52 (9.08) 44 (9.67)
Recessive model TT 1 (0.17) 0 (0.00) 0
GT + GG 572 (99.83) 455 (100.00)
Additive model GT 51 (8.90) 44 (9.67) 0
GG + TT 522 (91.10) 411 (90.33)
Allele G 1093 (95.38) 866 (95.16) 0
T 53 (4.62) 44 (4.84)
rs11572223
(SNP2)
Genotype Dominant model C/C 158 (59.62) 232 (53.83) 0
T/T 18 (6.79) 33 (7.66)
C/T 89 (33.58) 166 (38.52)
CC 158 (59.62) 232 (53.83) 0
CT + TT 107 (40.38) 199 (46.17)
Recessive model TT 18 (6.79) 33 (7.66) 0
CT + CC 247 (93.21) 398 (92.34)
Additive model CT 89 (33.58) 166 (38.52) 0
CC + TT 176 (66.42) 265 (61.48)
Allele C 405 (76.42) 630 (73.09) 0
T 125 (23.58) 232 (26.91)
rs2280275
(SNP3)
Genotype Dominant model C/C 167 (81.07) 204 (77.86) 0
T/T 2 (0.97) 5 (1.91)
C/T 37 (17.96) 53 (20.23)
CC 167 (81.07) 204 (77.86) 0
CT + TT 39 (18.93) 58 (22.14)
Recessive model TT 2 (0.97) 5 (1.91) 0
CT + CC 169 (82.04) 209 (79.77)
Additive model CT 37 (17.96) 53 (20.23) 0
CC + TT 169 (82.04) 209 (79.77)
Allele C 371 (90.05) 461 (87.98) 0
T 41 (9.95) 63 (12.02)
CAD, coronary artery disease.
The P value of genotype was calculated by Fisher's exact test. *P b 0.05.population). In the Uygur population, for total, the distribution of SNP3
(rs2280275) genotypes and additive model showed a signiﬁcant differ-
ence between CAD and control participants (P = 0.048 and P = 0.027
respectively). For total and men, the distribution of SNP3 (rs2280275)
alleles and the dominant model (CC vs CT + TT) showed a signiﬁcant
difference between CAD and control participants (for allele: P =
0.014 and P = 0.035, respectively; for dominant model: P = 0.014
and P = 0.034, respectively). T allele of rs2280275 was signiﬁcantly
higher in CAD patients than in control participants (total: 18.90% vs
12.29%; men: 18.57% vs 13.35%). The dominant model (CC vs
CT + TT) of rs2280275 was signiﬁcantly lower in CAD patients
than in control participants (total: 66.96% vs 75.00%; men: 66.91%
vs 75.27%). For the Han population, the distribution of the three
SNP genotypes and alleles showed no signiﬁcant difference between
the CAD patients and control subjects.
Table 3 shows that multiple logistic regression analyses were done
with Glu, LDL-C, EH, DM, and smoking because these variables were
the major confounding factors for CAD. For total and men, the signiﬁ-
cant difference of rs2280275 was retained after adjustment for Glu,
LDL-C, EH, DM, and smoking in Uygur population (for total participants,
OR: 0.279, 95% conﬁdence interval [CI]: 0.176–0.440, P = 0.001; and
for men, OR: 0.240, 95% CI: 0.128–0.457, P = 0.001).
4. Discussion
Several CYP enzyme families have been identiﬁed in the heart,
endothelium and smooth muscle of blood vessels. Increasing evi-
dence indicates the role of endogenous CYP metabolites such as
EETs, 20-hydroxyeicosatetraenoicacid, prostacyclin (PGI2), aldoste-
rone and sex hormones in the maintenance of cardiovascular health.
A link between the expression and activity of CYP and cardiovascularn).
Men Women
value CAD n (%) Control n (%) P value CAD n (%) Control n (%) P value
353 (89.59) 231 (90.23) 0.792 168 (93.85) 180 (90.45) 0.149
0 (0.00) 0 (0.00) 1 (0.56) 0 (0.00)
41 (10.41) 25 (9.77) 10 (5.59) 19 (9.55)
.745 353 (89.59) 231 (90.23) 0.792 168 (93.85) 180 (90.45) 0.153
41 (10.41) 25 (9.77) 11 (6.15) 19 (9.55)
.373 0 (0.00) 0 (0.00) – 1 (0.56) 0 (0.00) 0.474
353 (89.59) 231 (90.23) 178 (99.44) 199 (100.00)
.672 41 (9.43) 25 (9.77) 0.823 10 (5.59) 19 (9.55) 0.149
394 (90.57) 231 (90.23) 169 (94.41) 180 (90.45)
.823 747 (94.80) 489 (95.14) 0.785 346 (96.65) 379 (95.23) 0.325
41 (5.20) 25 (4.86) 12 (3.35) 19 (4.77)
.326 124 (59.33) 130 (54.39) 0.574 34 (60.71) 102 (53.13) 0.531
13 (6.22) 17 (7.11) 5 (8.93) 16 (8.33)
72 (34.45) 92 (38.49) 17 (30.36) 74 (38.54)
.135 124 (59.33) 130 (54.39) 0.293 34 (60.71) 102 (5.13) 0.315
85 (40.67) 109 (45.61) 22 (39.29) 90 (46.88)
.671 13 (6.22) 17 (7.11) 0.609 5 (8.93) 16 (8.33) 1
137 (65.55) 147 (61.51) 51 (91.07) 176 (91.67)
.19 72 (34.45) 92 (38.49) 0.375 17 (30.36) 74 (38.54) 0.264
137 (65.55) 147 (61.51) 39 (69.64) 118 (61.46)
.167 320 (76.56) 352 (73.64) 0.315 85 (83.33) 278 (72.40) 0.462
98 (23.44) 126 (26.36) 27 (26.47) 106 (27.60)
.567 125 (80.13) 110 (77.46) 0.709 42 (84.00) 94 (78.33) 0.795
1 (0.64) 2 (1.41) 1 (2.00) 3 (2.50)
30 (19.23) 30 (21.13) 7 (14.00) 23 (19.17)
.396 125 (80.13) 110 (77.46) 0.574 42 (84.00) 94 (78.33) 0.4
31 (19.87) 32 (22.54) 8 (16.00) 26 (21.67)
.395 1 (0.64) 2 (1.41) 0.607 1 (2.00) 3 (2.50) 1
155 (99.36) 140 (98.59) 49 (98.00) 117 (97.50)
.537 30 (19.23) 30 (21.13) 0.684 7 (14.00) 23 (19.17) 0.421
126 (80.77) 112 (78.87) 43 (86.00) 97 (80.83)
.317 280 (89.74) 250 (88.03) 0.525 91 (91.00) 211 (87.92) 0.456
32 (10.26) 34 (11.97) 9 (9.00) 29 (12.08)
Table 2b
Genotype and allele distributions in patients with CAD and control subjects (Uygur population).
Total Men Women
CAD n (%) Control n (%) P value CAD n (%) Control n (%) P value CAD n (%) Control n (%) P value
rs890293
(SNP1)
Genotype Dominant model G/G 253 (88.46) 125 (90.58) 0.669 213 (88.75) 82 (90.11) 0.773 40 (86.96) 43 (89.58) 0.692
T/T 1 (0.35) 0 (0.00) 1 (0.42) 0 (0.00) 0 (0.00) 0 (0.00)
G/T 32 (11.19) 13 (9.42) 26 (10.83) 8 (8.79) 6 (13.04) 5 (10.42)
GG 253 (88.46) 125 (90.58) 0.511 213 (88.75) 82 (90.11) 0.535 40 (86.96) 43 (89.58) 0.692
GT + TT 33 (11.54) 13 (9.42) 27 (11.25) 8 (8.79) 6 (13.04) 5 (10.42)
Recessive model TT 1 (0.35) 0 (0.00) 0.487 1 (0.42) 0 (0.00) 1 0 (0.00) 0 (0.00) –
GT + GG 285 (99.65) 138 (100.00) 239 (99.58) 90 (98.90) 46 (100.00) 48 (100.00)
Additive model GT 32 (11.19) 13 (9.42) 0.614 26 (10.83) 8 (8.16) 0.459 6 (13.04) 5 (10.42) 0.692
GG + TT 254 (88.81) 125 (90.58) 214 (89.17) 90 (91.84) 40 (86.96) 43 (89.58)
Allele G 538 (94.06) 263 (95.29) 0.462 452 (94.17) 172 (95.56) 0.484 86 (93.48) 91 (94.79) 0.701
T 34 (5.94) 13 (4.71) 28 (5.83) 8 (4.44) 6 (6.52) 5 (5.21)
rs11572223
(SNP2)
Genotype Dominant model C/C 224 (79.43) 242 (75.86) 0.215 185 (79.06) 127 (80.89) 0.442 39 (81.25) 114 (70.81) 0.358
T/T 11 (3.90) 8 (2.51) 10 (4.27) 3 (1.91) 1 (2.08) 5 (3.11)
C/T 47 (16.67) 69 (21.63) 39 (16.67) 27 (17.20) 8 (16.67) 42 (26.09)
CC 224 (79.43) 242 (75.86) 0.401 185 (79.06) 127 (80.89) 0.658 39 (81.25) 114 (70.81) 0.152
CT + TT 58 (20.57) 77 (24.14) 49 (20.94) 30 (19.11) 9 (18.75) 47 (29.19)
Recessive model TT 11 (3.90) 8 (2.51) 0.33 10 (4.27) 3 (1.91) 0.201 1 (2.08) 5 (3.11) 0.71
CT + CC 271 (96.10) 311 (97.49) 224 (95.73) 154 (98.09) 47 (97.92) 156 (96.89)
Additive model CT 47 (16.67) 69 (21.63) 0.124 39 (16.67) 27 (17.20) 0.891 8 (16.67) 42 (26.09) 0.179
CC + TT 235 (83.33) 250 (78.37) 195 (83.33) 130 (82.80) 40 (83.33) 119 (73.91)
Allele C 495 (87.77) 553 (86.68) 0.573 409 (87.39) 281 (89.49) 0.372 86 (89.58) 270 (83.85) 0.165
T 69 (12.23) 85 (13.32) 59 (12.61) 33 (10.51) 10 (10.42) 52 (16.15)
rs2280275
(SNP3)
Genotype Dominant model C/C 225 (66.96) 336 (75.00) 0.048* 182 (66.91) 140 (75.27) 0.154 43 (67.19) 196 (74.81) 0.34
T/T 16 (4.76) 16 (3.57) 11 (4.04) 5 (2.69) 5 (7.81) 11 (4.20)
C/T 95 (28.27) 96 (21.43) 79 (29.04) 41 (22.04) 16 (25.00) 55 (20.99)
CC 225 (66.96) 336 (75.00) 0.014* 182 (66.91) 140 (75.27) 0.034* 43 (67.19) 196 (74.81) 0.217
CT + TT 111 (33.04) 112 (25.00) 90 (33.09) 46 (24.73) 21 (32.81) 66 (25.19)
Recessive model TT 16 (4.76) 16 (3.57) 0.404 11 (4.04) 5 (2.69) 0.438 5 (7.81) 11 (4.20) 0.38
CT + CC 320 (95.24) 432 (96.43) 261 (95.96) 181 (97.31) 5992.19% 25195.80)
Additive model CT 95 (28.27) 96 (21.43) 0.027* 79 (29.04) 41 (22.04) 0.094 16 (25.00) 55 (20.99) 0.486
CC + TT 241 (71.73) 352 (78.57) 193 (70.96) 145 (77.96) 48 (75.00) 207 (79.01)
Allele C 545 (81.10) 768 (85.71) 0.014* 443 (81.43) 331 (86.65) 0.035* 102 (79.69) 447 (85.31) 0.118
T 127 (18.90) 128 (14.29) 101 (18.570 51 (13.35) 26 (20.31) 77 (14.69)
CAD, coronary artery disease.
The P value of genotype was calculated by Fisher's exact test. *P b 0.05.
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Table 3
Multiple logistic regression analysis for CAD patients and control subjects of Uygur population.
Total Men Women
OR 95% CI P OR 95% CI P OR 95% CI P
Dominant model (CC vs CT + TT) 0.279 0.176–0.440 0.001 0.24 0.128–0.457 0.001 0.615 0.291–1.302 0.204
Glu 1.249 1.139–1.370 0.001 1.239 1.092–1.406 0.001 1.374 1.143–1.653 0.001
LDL 0.896 0.799–1.003 0.057 0.912 0.878–1018 0.100 0.416 0.193–0.896 0.025
EH 6.541 3.946–10.842 0.001 9.92 4.83–20.403 0.001 4.002 1.765–9.074 0.001
DM 1.414 0.839–2.384 0.194 1.891 0.895–3.944 0.095 0.86 0.347–2.133 0.746
Smoking 8.18 5.254–12.735 0.001 10.121 5.609–18.264 0.001 0.221 0.028–1.734 0.151
EH, essential hypertension; DM, diabetes mellitus; CAD, coronary artery disease.
1052 Q. Zhu et al. / Clinical Biochemistry 46 (2013) 1047–1054disease (CVD) such as hypertension, CAD, heart failure, stroke, car-
diomyopathy and arrhythmias has been established [8]. In humans,
CYP2J2 acts mainly in converting arachidonic acid to EETs, and EETs
were rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the
corresponding dihydroxyeicosatrienoic acid (DHET). DHETs were
initially thought to be inactivation products of EETs, but several re-
cent studies indicate that, like EETs, they produce vasodilation and
activate smooth muscle BKCa channels. EETs have been established
to have ﬁve physiological functions. First, EETs produce vasodilation
in a number of vascular beds by activating the smooth muscle large
conductance Ca2+-activated K+ channels (BKCa) [23,31] (Fig. 2). Sec-
ond, EETs may play a role in the coronary circulation as endothelium-
derived hyperpolarizing factors (EDHF) [32]. EDHF possess potent
vasodilating effects and hyperpolarize vascular smooth muscle cellsFig. 2. Schematic of EET interactionswith cardiovascularion channels. A: In the cardiacmyocyte, E
endothelial small (SKCa) or intermediate (IKCa) conductance calcium-activated channels to
myoendothelial gap junctions. EETs also activate TRPV4 channels to activate Ca2+ inﬂux. In the v
through a G-protein-coupled event. C: In platelets, EETs activate BKCa channels.(VSMCs) by activating KCa [23,33,34]. Third, EETs inhibit inﬂammation
responses by decreasing the cytokine-induced endothelial expression
of vascular cell adhesion molecule-1 (VCAM-1) and decrease leukocyte
adhesion to the vascular wall by inhibiting nuclear factor κB (NF-κB)
and IκB kinase [35]. Fourth, EETs have antithrombotic effects by
inhibiting platelet adhesion to endothelial cells, inhibiting platelet ag-
gregation, and enhancing the expression and activity of tissue plasmin-
ogen activator [36]. Fifth, in the kidney, EETs are important regulators of
glomerular ﬁltration by activating Na+/H+ exchanger and mediate
pressure natriuresis and long-term control of blood pressure [37,38].
Polymorphisms of the CYP2J2 genemay affect themetabolismof arachi-
donic acid, resulting in an altered synthesis of EETs. In this study,we hy-
pothesized that variability in the gene might affect the risk of CAD. We
genotyped three SNPs of the gene in a Han population and an UygurETs activate sarcolemmal ormitochondrial KATP channels. B: In the vasculature, EETs activate
cause hyperpolarization, which can be transmitted to the vascular smooth muscle via
ascular smooth muscle, EETs activate large conductance, calcium-activated (BKCa) channels
1053Q. Zhu et al. / Clinical Biochemistry 46 (2013) 1047–1054population, and assessed the association between the polymorphism of
CYP2J2 gene and CAD using case–control analyses.
In the Uygur population, for total group, therewas a signiﬁcant differ-
ence in the genotypic distribution of SNP3 (rs2280275) between CAD
patients and control subjects.When analyzingmen andwomen separate-
ly, T allele frequency of rs2280275 was higher in CAD patients than in
control subjects in men. There was no difference of T allele between
CAD patients and control subjects in women. It meant that the risk of
CAD was increased with the T allele of rs2280275 in men. For total and
men, the dominant model (CC vs CT + TT) was signiﬁcantly lower in
CAD patients than in control subjects, and the signiﬁcant difference was
retained after adjustment for covariates such as Glu, LDL-C, EH, DM, and
smoking (Table 3). This indicated that the risk of CAD was decreased
with CC genotype of rs2280275 in men of Uygur population.
We found that there was the association between rs2280275 of
CYP2J2 gene and CAD only in male subgroup. This may be attributed to
sex hormones. Sex hormones such as estrogens protect against oxidative
stress and are known to be vasoprotective [39–41]. In addition, there
were some researches that reported estrogens protect the EETs against
being hydrolyzed by soluble epoxide hydrolase (sEH). [42,43].
Though SNP1 (rs890293) was observed in the proximal promoter re-
gion of the CYP2J2 gene, and the polymorphisms caused a loss of tran-
scription factor binding site Sp1, resulting in the synthesis of EETs was
reduced. The studies about the association between CYP2J2 polymor-
phisms (rs890293) and the cardiovascular risk have provided inconsis-
tent results. The study by Spiecker that showed a functionally relevant
polymorphism of the CYP2J2 gene (rs890293) independently was associ-
atedwith an increased risk of coronary artery disease [14]. This resultwas
supported by the study of Ping Yin Liu showing the polymorphism of
CYP2J2 (rs890293) was an important risk factor for the development of
MI in younger groups in Tainans [25]. In addition, a low risk of CAD was
reported by Lee in African-Americans carrying CYP2J2 variant alleles
(rs890293), but no signiﬁcant association was observed in Caucasians
[26]. There were several studies suggesting no signiﬁcant association be-
tween the polymorphism of CYP2J2 (rs890293) and CAD or MI [27,29],
and in a recent large sample case–control study and meta-analysis, they
also have not observed any signiﬁcant association between common
polymorphisms within CYP2J2 genes and CAD, whether using methods
of single-locus analysis or haplotype-based analysis [28]. Our study was
consistentwith the studies [27,28], showing no signiﬁcant association be-
tween the polymorphism of CYP2J2 (rs890293) and CAD. There may be
differences in populations and geographical factors to explain some dif-
ferences. For the SNP2 (rs11572223), our result was consistent with
Zeng Jie and his colleagues that the genotype and the allele distributions
of rs11572223 were not different between the CAD patients and control
subjects [44].5. Conclusion
In conclusion, we found that rs2280275 may be a novel polymor-
phism of the CYP2J2 gene associated with CAD in Uygur male population
in China. The CC genotype of rs2280275 in CYP2J2 gene could be a protec-
tive genetic marker of CAD and T allele may be a risk genetic marker of
CAD inmen of Uygur population in China. Certainly it needs a large num-
ber of clinical samples to study further in China.References
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